Clinical Trials Directory

Trials / Completed

CompletedNCT00704561

Vessel Wall Response of the Zotarolimus Drug-eluting Stent Implanted in AMI Assessed by Optical Coherence Tomography

Prospective, Randomized, Controlled Arm Study Comparing the Coverage of the Zotarolimus-eluting Stent vs Bare Metal Stent Implanted in ST- Elevation Myocardial Infarction (STEMI).

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
44 (actual)
Sponsor
A.O. Ospedale Papa Giovanni XXIII · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The objective of this study is to evaluate the completeness of struts coverage and vessel wall response (strut malapposition, neointima disomogeneities in texture) to the ENDEAVOR drug-eluting stent vs the DRIVER stent (bare metal stent of identical metallic platform) implanted for the treatment of the culprit lesion in ST-elevation acute myocardial infarction (STEMI). To investigate the completeness of the coverage as well as the number of uncovered stent struts per section (embedded, uncovered, malapposed) and the neointima texture, high resolution (\~ 10-15 µm axial) intracoronary optical coherence tomography (OCT)will be used.

Detailed description

Major concerns have been raised with regard to the safety of drug-eluting stents (DES) in patients with ST-elevation acute myocardial infarction (STEMI). Data from registry studies have suggested that implantation of DES during primary PCI could be associated with an increased risk for stent thrombosis, probably due to delayed arterial healing. Unlike first generation DES, zotarolimus-eluting stents seems to be associated with complete and uniform neointimal coverage. The objective of this prospective study is to measure the completeness of strut coverage and vessel wall response to the ENDEAVOR zotarolimus-eluting stent vs the DRIVER stent (bare metal stent of identical metallic platform) implanted in STEMI patients. Optical Coherence Tomography (OCT) that detects smaller degrees of stent strut coverage more accurately than IVUS will be used at 6 months follow-up. Intravascular ultrasound (IVUS) will be performed as per normal practice at any index procedures and at 6 months follow-up.

Conditions

Interventions

TypeNameDescription
DEVICEENDEAVOR® drug-eluting stent (Medtronic, Santa Rosa, CA)ENDEAVOR® drug-eluting stent implanted in acute myocardial infarction
DEVICEDRIVER bare metal stent (Medtronic, Santa Rosa, Ca)DRIVER bare metal stent implanted in acute myocardial infarction
DEVICECoronary stent implantationComparison of Drug Eluting versus Bare Metal Stent
DEVICEBare Metal Coronary StentComaprison between Drug Eluting and Bare Metal Coronary Stents

Timeline

Start date
2008-04-01
Primary completion
2009-04-01
Completion
2009-10-01
First posted
2008-06-25
Last updated
2022-05-23

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT00704561. Inclusion in this directory is not an endorsement.